Portrait SLAS Europe 2025: New Home Port Hamburg
This year, Hamburg will host one of the most significant events in the automation and screening industry: the SLAS Europe Conference and Exhibition will take place in the Hanseatic city for the first time. Philip Gribbon, President of the Society for Laboratory Automation and Screening (SLAS) for 2025, is delighted by the choice of Hamburg […]
Business Nord Pharmaceutical Production in the North: An Overview
Northern Germany is home to renowned pharmaceutical manufacturers with a global reach. This region is a hub for key industry players involved in pharmaceutical production, ranging from innovative small and medium-sized enterprises to multinational corporations. There are some that are leaders in their fields. Northern Germany, particularly Hamburg and Schleswig-Holstein, has become an increasingly attractive […]
Science & Translation BlueHealthTech alliance yields results
Innovative health technologies from the sea are taking shape in the Kiel region. In order to transfer knowledge from marine research into medical applications, the BlueHealthTech innovation alliance brings together regional partners from science, healthcare and business. One of many impressive examples is the company osteolabs, which aims to enable life-saving early diagnoses for numerous diseases.
A major boost for biopharma manufacturing in the North
Biopharmaceuticals made in Schleswig-Holstein: In this interview, Richter BioLogics CEO Kai Pohlmeyer explains why the contract manufacturer has invested 100 million euros in the expansion of its plant in Bovenau and what this means for the Cluster Life Science Nord.
Business Nord|Innovation|Science & Translation HIV gene-editing therapy heads to the clinic
Provirex’ innovative genome editing therapy enables the elimination of persistent viral genomes from infected cells. The start-up is building a therapy hub in the future Science City Hamburg Bahrenfeld.
Science & Translation Gene and Cell Therapies: Shaping the National Strategy
The recently published National Strategy for Gene and Cell-Based Therapies is intended to link the players in this innovative field of medicine throughout Germany and to speed up the introduction of treatment approaches into clinical care. Four experts from Hamburg were involved in the development of the strategy. What is most important to them?